<DOC>
	<DOCNO>NCT00376428</DOCNO>
	<brief_summary>Suppression stop mutation CFTR gene parenteral gentamicin predict vitro associate clinical benefit significant modification CFTR-mediated chloride transport nasal sweat gland epithelium .</brief_summary>
	<brief_title>Interest Gentamicin-induced Readthrough Cystic Fibrosis Patients</brief_title>
	<detailed_description>Background : This study conduct determine whether intravenous gentamicin suppress stop codon cystic fibrosis ( CF ) patient , , whether clinical benefit . Methods : We first use dual gene reporter system determine gentamicin-induced readthrough level frequent CFTR stop mutation French population . We next investigate readthrough efficiency response 10 mg/kg daily intravenous gentamicin perfusion patient stop mutation control group patient without stop mutation . Respiratory function , sweat chloride concentration , nasal potential difference ( NPD ) CFTR expression nasal epithelial cell measure baseline 15 day treatment . Results : After vitro gentamicin incubation , readthrough efficiency Y122X mutation least five time higher G542X , R1162X , W1282X . In six nine patient Y122X mutation , CFTR immunodetection show protein expression membrane nasal ciliated cell CFTR-dependent chloride secretion NPD measurement increase significantly . Respiratory status also improve patient , irrespective gentamicin sensitivity germ present sputum . Mean sweat chloride concentration decrease significantly normalize two patient . These measurement change Y122X patient protein expression , patient stop mutation investigate vitro ( n=4 ) without stop mutation ( n=5 ) . Conclusion : Suppression stop mutation CFTR gene parenteral gentamicin predict vitro associate clinical benefit significant modification CFTR-mediated chloride transport nasal sweat gland epithelium .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Gentamicins</mesh_term>
	<criteria>cystic fibrosis CFTR codon stop mutation Rhinitis nasal polyposis passive active smoking modification basal treatment within previous month treatment aminoglycosides within three previous month</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Cystic Fibrosis Transmembrane Conductance Regulator</keyword>
	<keyword>Premature termination codon</keyword>
	<keyword>Gentamicin-induced readthrough</keyword>
</DOC>